HALO * logo

Halozyme Therapeutics BMV:HALO * Stock Report

Last Price

Mex$680.00

Market Cap

Mex$88.8b

7D

0%

1Y

0.04%

Updated

20 Dec, 2023

Data

Company Financials +

Halozyme Therapeutics, Inc.

BMV:HALO * Stock Report

Market Cap: Mex$88.8b

HALO * Stock Overview

A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. More details

HALO * fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance3/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 67% below our estimate of its fair value

Earnings are forecast to grow 24.14% per year

Earnings grew by 20.2% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Halozyme Therapeutics, Inc. Competitors

Xiamen Amoytop Biotech

SHSE:688278

CN¥32.3b

Biocon

NSEI:BIOCON

₹416.7b

ADMA Biologics

NasdaqGM:ADMA

US$4.7b

Sarepta Therapeutics

NasdaqGS:SRPT

US$7.2b

Price History & Performance

Summary of share price highs, lows and changes for Halozyme Therapeutics
Historical stock prices
Current Share PriceUS$680.00
52 Week HighUS$680.00
52 Week LowUS$680.00
Beta1.25
1 Month Change0%
3 Month Changen/a
1 Year Change0.038%
3 Year Changen/a
5 Year Changen/a
Change since IPO-19.23%

Recent News & Updates

Recent updates

Shareholder Returns

HALO *MX BiotechsMX Market
7D0%0%0%
1Y0.04%0%0%

Return vs Industry: HALO * exceeded the MX Biotechs industry which returned -1.3% over the past year.

Return vs Market: HALO * underperformed the MX Market which returned 9.1% over the past year.

Price Volatility

Is HALO *'s price volatile compared to industry and market?
HALO * volatility
HALO * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: HALO * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HALO *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998393Helen Torleyhalozyme.com

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

Halozyme Therapeutics, Inc. Fundamentals Summary

How do Halozyme Therapeutics's earnings and revenue compare to its market cap?
HALO * fundamental statistics
Market capMex$88.79b
Earnings (TTM)Mex$4.33b
Revenue (TTM)Mex$13.33b

20.5x

P/E Ratio

6.7x

P/S Ratio

Is HALO * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HALO * income statement (TTM)
RevenueUS$780.71m
Cost of RevenueUS$259.78m
Gross ProfitUS$520.93m
Other ExpensesUS$267.03m
EarningsUS$253.91m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.92
Gross Margin66.73%
Net Profit Margin32.52%
Debt/Equity Ratio601.0%

How did HALO * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/20 16:39
End of Day Share Price 2023/09/22 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 35 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Robert WassermanBenchmark Company